Emergency Care Partners finalizes its merger with Chicago’s IEMS
Category: #health  By Pankaj Singh  Date: 2019-09-18
  • share
  • Twitter
  • Facebook
  • LinkedIn

Emergency Care Partners finalizes its merger with Chicago’s IEMS

With rising cases of roadside accidents worldwide, the need for emergency medical facilities have increased considerably in recent years. These facilities offer immediate assistance without any appointments, which makes them the go-to place for treating diseases and injuries.

Emergency Care Partners (ECP) is one such provider of outsourced emergency department management services and emergency medicine to medical facilities around New York, Pennsylvania and Louisiana. The company has recently finalized its strategic merger with IEMS (Illinois Emergency Medicine Specialists), a medical group that offers outsourced emergency department management services.

Speaking on the move, Bill Yarbrough, CEO, Emergency Care Partners, said that the company is thrilled to accept IEMS as a group member. Moreover, the strength of IEMS’s local health system relationships and its vast experience as physician partners makes it the perfect addition to their company’s national group.

Reportedly, the newly formed emergency medicine service will offer departmental operations at 26 clinics and hospitals, along with a shared clinical staff of 600 mid-level providers and physicians, handling an estimate of 900,000 ER patient visits yearly.

Sources cite that IEMS’s physician partners will also join ECP shareholders along with Ted Patras, M.D., who will stay as the President of the Chicago based emergency medicine specialist.

Incidentally, the U.S. healthcare sector is witnessing numerous mergers lately. For instance, recently WellNow Urgent Care, a New York-based leading providers of urgent care, ventured with St. Peter's Health Partners that would add both the firms name on two WellNow’s operations and six operating locations handled by St. Peter's in the Capital Region.

Reportedly, WellNow's Hudson and Niskayuna facilities will be the initial places that would be redesigned as co-branded facilities. The centers will be open 24/7 and will not need any prior appointments.

Moreover, they would have professional medical personnel that would treat non-life-threatening illnesses and injuries like abrasions, burns, coughs, dehydration, sprains, colds, strains and several other cases.

As for the merger with ECP, Dr. Ted Patras, M.D., President, IEMS, said that their company is delighted with the opportunities to join with ECP’s team as the new partnership would enable it to provide the best patient experiences and quality outcomes, and to bring enhanced efficiencies for the complete health system.

Source Credit: https://finance.yahoo.com/news/emergency-care-partners-joins-illinois-180000744.html



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Anova Enterprises expands AnovaOS™ to boost clinical development
Anova Enterprises expands AnovaOS™ to boost clinical development
By Pankaj Singh

The U.S-based Anova Enterprises, Inc. (Anova) has reportedly expanded the AnovaOS™ technology platform in order to boost the development of promising novel treatments. The platform brings pharmaceutical companies...

Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
Serum Institute to Resume Oxford COVID-19 Vaccine’s Trail in India
By Pankaj Singh

India’s Drugs Controller General (DCGI) has approved Pune-based Serum Institute of India (SII) to restart the clinical trial of the Oxford/AstraZeneca COVID-19 vaccine in India.

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results

Everest Medicines Announces Cefepime-Taniborbactam Phase 1 Results
By Pankaj Singh

Everest Medicines announced the top-line results from the Phase 1 clinical trial of Taniborbactam with cefepime for treating infections caused by multi-drug resistant pathogens in China. Everest Medicines is a biopharm...